Author(s): Karabudak R, Karampampa K, Calkan Z TRIBUNE St
Abstract Share this page
Abstract OBJECTIVE: To estimate the economic burden of multiple sclerosis (MS) in Turkey, including the relapses and disease severity, and to evaluate the quality-of-life of MS patients. METHODS: The Treatment Experience, Burden and Unmet Needs (TRIBUNE) study was a multi-national, cross-sectional, retrospective, burden-of-illness survey. Total costs were calculated using unit costs derived from price lists or published literature, where relevant, and inflated to 2011 TL prices. RESULTS: A total of 295 MS patients (74\% females) were included in the analysis. The population had a mean age of 36 years; 73\% had the relapsing-remitting form. Mean Expanded Disability Status Scale (EDSS) score was 2.2. Twenty-two per cent of the MS patients required hospitalization in the past year and spent an average of 29.2 days/year in hospital. These values were 43\% and 5.6 days for the outpatients, respectively. Total cost per patient/year was 18,700 TL (Turkish Lira). Total costs for patients with mild, moderate, and severe disability were 15,418 TL, 26,002 TL, and 44,208 TL per patient/year, respectively. The mean EuroQol 5D scores in the same groups were 0.73, 0.52, and 0.05, respectively. CONCLUSIONS: Multiple sclerosis imposes a significant economic burden on patients and society in Turkey.
This article was published in J Med Econ
and referenced in Pharmacoeconomics: Open Access